Pleiotropic use of Statins as non-lipid-lowering drugs

Int J Biol Sci. 2020 Aug 13;16(14):2704-2711. doi: 10.7150/ijbs.42965. eCollection 2020.

Abstract

Statins, known as HMG-CoA reductase (HMGCR) inhibitors, have primarily been utilized for metabolic and angiographic medical applications because of their cholesterol-lowering effects. Similar to other drugs, statins may also induce a series of potential side effects. Statins inhibit the HMGCR (rate-limiting enzyme) activity in early stages of mevalonate pathway and then indirectly affect a number of intermediate products, including non-sterol isoprenoids (coenzyme Q10, dolichol etc.), which can result in impaired functions of body organs. Recently, scores of studies have uncovered additional functional mechanisms of statins in other diseases, such as diabetes mellitus, nervous system diseases, coronary heart disease, inflammation and cancers. This review aims to summarize the positive and adverse mechanisms of statin therapy. Statin care should be taken in the treatment of many diseases including cancers. Since the underlying mechanisms are not fully elucidated, future studies should spend more time and efforts on basic research to explore the mechanisms of statins.

Keywords: Statins; anticancer agents; mevalonate pathway; non-lipid-lowering function.

Publication types

  • Review

MeSH terms

  • Coronary Disease / drug therapy
  • Diabetes Mellitus / chemically induced
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Inflammation / drug therapy
  • Neoplasms / drug therapy
  • Nervous System Diseases / drug therapy

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors